2015
DOI: 10.1161/circinterventions.114.002372
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and Safety of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent

Abstract: Background-Drug eluting stents with durable polymers may be associated with hypersensitivity, delayed healing, and incomplete endothelialization, which may contribute to late/very late stent thrombosis and the need for prolonged dual antiplatelet therapy. Bioabsorbable polymers may facilitate stent healing, thus enhancing clinical safety. The SYNERGY stent is a thin-strut, platinum chromium metal alloy platform with an ultrathin bioabsorbable Poly(D,L-lactide-co-glycolide) abluminal everolimus-eluting polymer.… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

12
131
2
1

Year Published

2015
2015
2022
2022

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 228 publications
(146 citation statements)
references
References 26 publications
12
131
2
1
Order By: Relevance
“…Important factors to consider in perioperative DAPT management are the type, number, and size of stents versus the risk of delaying renal transplantation in favor of prolonging DAPT to prevent stent thrombosis. A newer generation of DESs with enhanced biocompatibility and reduced thrombogenicity may require only 1 to 6 months of DAPT depending on the type of stent, but more evidence is needed 61, 66, 67. These considerations highlight the fact that DAPT should be tailored to the individual patient.…”
Section: Cad In Patients With Esrdmentioning
confidence: 99%
“…Important factors to consider in perioperative DAPT management are the type, number, and size of stents versus the risk of delaying renal transplantation in favor of prolonging DAPT to prevent stent thrombosis. A newer generation of DESs with enhanced biocompatibility and reduced thrombogenicity may require only 1 to 6 months of DAPT depending on the type of stent, but more evidence is needed 61, 66, 67. These considerations highlight the fact that DAPT should be tailored to the individual patient.…”
Section: Cad In Patients With Esrdmentioning
confidence: 99%
“…target lesion revascularization rates were 4.0% with BP-SES and 3.1% with PP-EES (rate ratio, 1.30; 95% CI, 0.82-2.06; P=0.27), whereas the incidence of definite/probable stent thrombosis was numerically lower with BP-SES (2.8%) compared with P-EES (3.4%; rate ratio, 0.83; 95% CI, 0.50-1.35; P=0. 45). 38 To highlight is the very low in-stent LLL observed with the ultrathin Orsiro stent (0.1 mm), which is also identical to the in-stent LLL observed with the BP-EES (Synergy stent; Boston Scientific Corp).…”
Section: Bp-based Dessmentioning
confidence: 53%
“…In the Assess the Synergy Stent System for the Treatment of Atherosclerotic Lesion(s) (EVOLVE II) trial, target lesion failure at 1 year was virtually identical with both BP-EES and PP-EES (Promus Element stents; Boston Scientific Corp)-6.7% versus 6.4% respectively (P noninferiority =0.0003). 45 In the Randomized MicroPort's Firehawk DES Versus Xience V (TARGET I) trial, the Firehawk stent (86-μm cobalt-chromium with abluminal grooves filled with polylactide acid and sirolimus; Microport Medical, Shangai, China) was noninferior to PP-ESS on the primary end point 9-month instent LLL (0.13±0.24 versus 0.13±0.18 mm, respectively; P noninferiority <0.001). 56 Another concept is tested in the design of BP-SES (MiStent platform; Micell Technologies, Durham, NS).…”
Section: Bp-based Dessmentioning
confidence: 99%
“…The drug and polymer coating is absorbed by 3 months. 17 Recently, the polymer-free biolimus A9 stent was tested against bare metal stents in patients with a high risk of bleeding, and it was found to be superior with lower rates of target vessel revascularization and similar safety despite only 1 month of dual-antiplatelet therapy. 18 Further refinements in coating and stent design are likely to continue to reduce late complications.…”
Section: Coronary Artery Interventions the Current Status Of Coronarymentioning
confidence: 99%